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Abstract
Background—Cannabis is a commonly used drug and studies have shown that a significant 
portion of the variation in cannabis use disorders (CUDs) is heritable. Five genes known to play a 
role in the endocannabinoid system and CUDs were examined in a community sample of young 
adult Mexican Americans (MAs): CNR1, MGLL, FAAH, DAGLA, and DAGLB.
Methods—Gene-based tests were run to test for association between each gene and two DSM-5 
cannabis phenotypes. Subsequent linear regressions were run in PLINK using an additive model to 
determine which single nucleotide polymorphisms (SNPs) were driving the association.
Results—FAAH was significantly associated with DSM-5 cannabis use disorder group count 
(DSM-5 CUD) using a gene-based test (p = 0.0035). This association survived Bonferroni 
correction for multiple testing at p < 0.004. Post hoc analyses suggested this association was 
driven by two common (minor allele frequency > 5%) SNPs in moderate linkage disequilibrium, 
rs324420 and rs4141964, at p = 0.0014 and p = 0.0023, respectively. In both cases the minor allele 
increased risk for DSM-5 CUD.
Conclusions—Genetic variation in FAAH was associated with DSM-5 CUD in MAs. This 
association was primarily driven by the missense SNP rs324420. In vitro work has provided 
evidence that the risk allele generates an enzyme with decreased expression and cellular stability. 
Although this SNP has been previously associated with substance use in the literature, this is the 
first association in a young adult MA sample.
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1. INTRODUCTION
Cannabis is the most widely used substance, second to alcohol, in the U.S. (National 
Institute on Drug Abuse, 2016). The brain’s endogenous endocannabinoid system (ECS) is 
comprised of cannabinoids (endocannabinoids, eCBs), cannabinoid receptors, and enzymes 
responsible for the synthesis and degradation of eCBs. The two major ligands in the ECS are 
arachidonoyl ethanolamide (anandamide, AEA) and 2-arachidonoyl glycerol (2-AG) (see Lu 
and Mackie, 2016 for review). Unlike other neurotransmitters, typically synthesized and 
stored in synaptic vesicles, AEA and 2-AG are synthesized “on demand” from precursors 
present in lipid membranes. Specifically, AEA is manufactured from N-arachidonoyl 
phosphatidyl ethanol. 2-AG is produced by a two-step hydrolysis: first, an arachidonoyl-
containing phosphatidyl inositol bis-phosphate is hydrolyzed into a diacylglycerol (DAG); 
and second, DAG is hydrolyzed into 2-AG by two DAG lipases (encoded by DAGLA and 
DAGLB). Once released into the synapse, eCBs primarily bind the cannabinoid type 1 and 2 
receptors (CB1 and CB2, encoded by CNR1 and CNR2, respectively). CB1 is the primary 
eCB receptor at which AEA and 2-AG have higher efficacy than at CB2 receptors. CB1 is 
also abundantly expressed in the central nervous system (CNS). Catabolism of AEA and 2-
AG is predominantly carried out by fatty acid amide hydrolase (FAAH) and monoglyceride 
lipase (MGLL), respectively. Endocannabinoid receptors also bind Δ9-tetrahydrocannabinol, 
the psychoactive component present in cannabis (Mechoulam and Gaoni, 1965), and can 
cause a myriad of changes depending on the experimental conditions. Thus, the ECS is a 
promising system for candidate gene (CG) studies of cannabis use disorders (CUDs).
A recent meta-analysis estimated that 51–59% of the variation in CUDs is attributed to 
genetic influences (Verweij et al., 2010). Linkage peaks have been observed around genes 
pertinent to the ECS, including CNR1 and MGLL (Agrawal et al., 2008; Ehlers et al., 2010; 
Hopfer et al., 2007). However, CG studies on CUDs have been inconsistent (reviewed in 
(Agrawal and Lynskey, 2009; Buhler et al., 2015)) and genome-wide association studies on 
CUDs have yielded no genome-wide significant hits (Agrawal et al., 2011, 2014; Minica et 
al., 2015; Verweij et al., 2013), consistent with results from a recent meta-analysis (Stringer 
et al., 2016).
In this study, we tested the hypothesis that genetic variation in ECS-related genes is 
associated with CUDs in a sample of Mexican Americans (MAs). The racial/ethnic 
composition of the U.S. is changing rapidly with the nonwhite segment of the population 
expanding faster than whites. In California, the population of individuals of Hispanic 
heritage, who are primarily MA, is currently predicted to be the majority population by the 
end of the decade. Thus, understanding heath disparities in this ethnic group is a major 
public health concern. A recent national survey found that past year cannabis users who 
were Hispanic had higher odds of CUD than whites (Wu et al., 2014), yet the unique risk 
factors that may contribute to this risk remain largely unknown. We used a gene-based 
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analysis to look at genetic variation in CNR1, MGLL, FAAH, DAGLA, and DAGLB, based 
on prior evidence for association with CUDs and/or their direct role in the ECS. Specifically, 
two gene-based tests were used to: 1) replicate genetic associations in the literature, which 
have primarily focused on common variants in European Americans, and 2) investigate rare 
variants specific to this population of MAs for association with CUDs.
2. MATERIALS AND METHODS
Data were derived from a cohort of 619 MAs, as previously described (Ehlers et al., 2011). 
Briefly, these subjects were recruited using a commercial mailing list that supplied the 
addresses of individuals with Hispanic surnames in 11 zip codes in San Diego County. 
Participants were required to be of Hispanic heritage, between 18 and 30 years old, living in 
the U.S. legally, and able to read and write in English; exclusionary criteria included being 
pregnant or nursing, or having a major medical or neurological disorder or injury. Hispanic 
heritage was self-reported and based on the origin of each subject’s 8 grandparents. 97.9% 
of the sample self-identified as having 12.5% or more Hispanic heritage and 91.4% as 
having 50% or more Hispanic heritage. 83.8% of the sample had 50% or more Mexican 
heritage alone.
The Semi-Structured Assessment for the Genetics of Alcoholism (Bucholz et al., 1994), a 
well-documented and reliable resource for diagnosing substance use (SU) behaviors 
(Bucholz et al., 1994; Hesselbrock et al., 1999), was used to collect information for several 
cannabis phenotypes. However, given the nested nature of some phenotypes, as well as high 
correlations between them (e.g. the DSM-IV and DSM-5 phenotypes), we focused on the 
following two DSM-5 phenotypes: DSM-5 cannabis use disorder group count (DSM-5 
CUD, quantitative), and having moderate or severe CUD by DSM-5 (DSM-5 MSU, 
dichotomous). The Institutional Review Board of the Scripps Research Institute approved 
the protocol for this study. Written consent was obtained from all participants.
DNA was extracted from blood samples and subsequently prepared and genotyped using the 
Affymetrix Exome1A chip as previously described (Norden-Krichmar et al., 2014). Initial 
quality control was performed according to Affymetrix best practices (Affymetrix, 2011). In 
addition, single nucleotide polymorphisms (SNPs) out of Hardy-Weinberg Equilibrium 
(HWE) at p-value<10−10 were removed, as were SNPs with bad genotype clusters. Genome-
wide Complex Trait Analysis (Yang et al., 2011) was used to remove subjects of high hidden 
relatedness (genetic relationship cutoff 0.125) and calculate principal components (PCs). 
Gender, age, and 20 PCs were included as covariates in all analyses.
Variants were annotated to genes using the Affymetrix Exome1A chip description file. No 
minor allele frequency (MAF) cutoff was applied. The gene test was performed in R (R 
Development Core Team, 2012) with the Sequence Kernel Association Test (SKAT; Wu et 
al., 2011) package. This test allows for variants that differ in direction and magnitude of 
effect. We used two specific algorithms within this method: SKAT-O, an extension of SKAT 
in which an optimal test is derived from a burden and typical SKAT analysis (Lee et al., 
2012); and SKAT_CommonRare, in which the combined effect of rare and common variants 
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is tested (Ionita-Laza et al., 2014). Tests were run using all default parameters (with the 
exception of method=“optimal.adj” as opposed to “davis” for the SKAT-O test).
Multiple test correction for each hypothesis was employed as follows. First, to correct for 
the number of phenotypes tested, the effective number of independent phenotypes was 
calculated using the variance of the eigenvalues of the phenotype correlation matrix after 
correction for covariates (Cheverud, 2001; Nyholt, 2004). The Bonferroni corrected 
significance threshold was calculated at 0.004 by dividing 0.05 by the number of genes 
multiplied by the effective number of independent phenotypes.
In order to determine which variants were driving the gene-wise association, post hoc 
analyses were performed by running linear regressions in PLINK (Purcell et al., 2007) on 
each SNP in the associated gene using an additive model. PLINK was used to calculate 
MAF and linkage disequilibrium (LD).
3. RESULTS
Five hundred and forty eight subjects (228M, 320F) were used in the analysis, 389 (70.99%) 
of whom had used cannabis. The mean age at the time of interview was 23.70yrs. Additional 
sample demographics are provided in Supplementary Table 11.
No genes were associated with DSM-5 CUD or DSM-5 MSU using SKAT-O (results not 
shown). FAAH was associated with DSM-5 CUD using SKAT_CommonRare (Table 1). 
This association survived Bonferroni correction for multiple testing at p<0.004. A complete 
list of SNPs included in each gene-based test is provided in Supplementary Table 22. Lack 
of association using SKAT-O and association using SKAT_CommonRare suggested these 
results were driven by the common variants. Univariate tests with the common SNPs in 
FAAH and DSM-5 CUD confirmed this; two common SNPs, rs4141964 and rs324420, were 
driving the association (Table 2). These SNPs were in LD (R2=0.585 and D′=0.988), and in 
both cases the minor allele was shown to increase risk for DSM-5 CUD.
4. DISCUSSION
In the present study, five genes known to play a role in the ECS were tested for association 
with CUDs using a gene-based test; FAAH was associated with DSM-5 CUD after 
correction for multiple testing. Two previous studies have examined genetic variation in 
targeted ECS genes using a gene-based test; however, FAAH was not associated with 
cannabis use (Verweij et al., 2012) or cannabis dependence (Carey et al., 2015). This finding 
is not altogether surprising, given that these phenotypes differ from the construct used in the 
present study, and our MA subjects represent an ethnically unique sample at high risk for 
developing alcoholism (Criado and Ehlers, 2007; Ehlers and Phillips, 2007). Indeed most 
subjects with DSM-5 MSU had a comorbid DSM-5 alcohol use disorder.
1Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:...
2Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:...
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Subsequent analyses revealed two correlated SNPs driving the association with FAAH and 
DSM-5 CUD: rs324420, a missense SNP resulting in the conversion of a proline to a 
threonine; and rs4141964, an intronic SNP. Although some studies have not detected an 
association between rs324420 and SU (Haughey et al., 2008; Proudnikov et al., 2010; 
Verweij et al., 2012), particularly in Asian populations (Iwasaki et al., 2007; Morita et al., 
2005), the literature overwhelmingly supports a role for rs324420 in SU (Buhler et al., 2014; 
Flanagan et al., 2006). While one study found that subjects homozygous for the minor allele 
were 0.25 times less likely to be cannabis dependent (Tyndale et al., 2007), our results 
suggesting the A allele increases risk for CUDs are in line with previous findings (Li et al., 
2011; Sipe et al., 2002). In addition, the A allele produces a defective mutant enzyme with 
reduced expression and stability (Chiang et al., 2004). Only one study investigated the effect 
of rs4141964 in SU; in a multi-ethnic study, Bidwell and colleagues (2013) found a 
significant main effect of a FAAH haplotype containing the minor alleles of rs4141964 and 
rs324420 that predicted higher marijuana-related problems. Thus, our results concur with the 
current literature and suggest that the minor alleles of rs4141964 and rs324420 are 
associated with CUDs.
CNR2 was not included in the original analysis because it is primarily expressed in the 
periphery (Munro et al., 1993). However, a post hoc gene-test was run on CNR2 based on 
accumulating evidence for CNR2 expression in the CNS (reviewed in (Onaivi et al., 2006a)) 
and involvement in SU (Ishiguro et al., 2007; Onaivi et al., 2006b, 2008). Although only 
three SNPs were included, CNR2 was not associated with DSM-5 CUD or MSU 
(Supplementary Table 33).
This study has several strengths and limitations. Gene-based tests are a more powerful 
alternative to single SNP tests, and by testing specific CGs we sidestepped several 
drawbacks when examining already curated gene tests (Wang et al., 2011). SKAT has higher 
power than several other burden tests to detect genetic effects (Wu et al., 2011). However, 
we were limited by what SNPs were genotyped on the Affymetrix Exome1A chip and were 
annotated to our target genes by the Affymetrix Exome1A chip description file, and thus 
important signals may have been missed in each gene. Due to the modest sample size, which 
could lead to false negatives, subjects who had never used cannabis were included. There are 
two reasons why this likely does not mitigate the results of this study: 1) a recent meta-
analysis suggested that environmental influences play a larger role in cannabis initiation than 
CUD (Verweij et al., 2010), and 2) there may be some overlap in genetic influences between 
cannabis initiation and CUD (Agrawal et al., 2005; Fowler et al., 2007; Gillespie et al., 
2009). Finally, as with other human genetic studies, replication is needed to support our 
findings. However, the exclusivity of the sample is both a strength and limitation; this 
sample is primarily of MA ancestry and has been previously shown to have a high risk of 
developing alcoholism (Criado and Ehlers, 2007; Ehlers and Phillips, 2007).
The present study provided evidence for a role of FAAH in CUDs in MAs. This association 
was primarily driven by a missense SNP in FAAH that has been previously associated with 
3Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:...
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SU in the literature and shown to influence enzyme stability. This is the first association 
between SNPs in FAAH and DSM-5 CUD in a young adult MA sample.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Genetic variation in FAAH was associated with DSM-5 cannabis use 
disorder.
• CNR1, MGLL, DAGLA, and DAGLB were not associated with DSM-5 
cannabis use disorder.
• Previous associations with rs324420 and cannabis use disorders were 
replicated.
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